Previously, we demonstrated that the combinatorial treatment of human HCC cell lines—i.e., Huh7, HepG2 and Hep3B—with AKT and mTOR inhibitors led to synergistic effects on cell growth in vitro and in vivo [38]. The gene discussed is AKT1; the disease is hepatocellular carcinoma.